epocrates logo
epocrates logo
epocrates logo
  • 0

Diseases

Evaluation of secondary amenorrhea

OVERVIEW

  • Summary
  • Urgent Considerations
  • Etiology

DIAGNOSIS

  • Differential Diagnosis
  • Diagnostic Approach

IMAGES

  • Library

REFERENCES

  • Citations
  • Credits

Summary

AAFont SizeShareMore Information
Amenorrhea is the transient or permanent absence of menstrual flow. There is no consensus on the definition of amenorrhea, but it may be subdivided into primary and secondary amenorrhea as follows:[1]​
  • Primary amenorrhea: lack of menses by age 15 years in a patient with appropriate development of secondary sexual characteristics, or lack of menses within 5 years of breast development if breast development occurred before age 10 years

  • Secondary amenorrhea: lack of menses for >3 months in a nonpregnant female who previously had regular menstrual cycles, or lack of menses for 6 months in a female who previously had irregular menstrual cycles.

Although attributes overlap between the two groups, the diagnostic approaches vary significantly.
Contemporary population-level evidence regarding the incidence and prevalence of amenorrhea is scarce.
The prevalence of secondary amenorrhea is estimated to be 3% to 4%; primary amenorrhea is considerably less common (<0.1%).[2] [3] [4]​​
Prevalence of secondary amenorrhea appears to be higher among women who participate in physically demanding sports or disciplines, including cycling (56%), triathlon (40%), rhythmic gymnastics (31%), and ballet (20% to 23%).[5] [6] [7]​
Common causes of secondary amenorrhea include polycystic ovary syndrome, hypothalamic dysfunction, premature ovarian insufficiency, and hyperprolactinemia.[1] [8] [9]​​
In general, amenorrhea accounts for a relatively small percentage of patient visits, even at highly specialized centers.
A prompt, comprehensive assessment is warranted unless the patient is pregnant, lactating, or using hormonal contraceptives, as amenorrhea is often the presenting sign of an underlying reproductive disorder. A delay in diagnosis and treatment may adversely impact health outcomes of such patients. For example, in polycystic ovary syndrome and hyperinsulinemia, behavioral and dietary modifications may prevent subsequent cardiovascular disease.
content by BMJ Group
Last updated

Library

  • World Health Organization classification of amenorrhea

    World Health Organization classification of amenorrhea

  • Androgen-secreting tumor in cut section of right ovary

    Androgen-secreting tumor in cut section of right ovary

  • Polycystic ovarian ultrasound

    Polycystic ovarian ultrasound

  • (A) Coronal T1-weighted MRI scan showing a pituitary mass with expansion of the pituitary fossa (B)

    (A) Coronal T1-weighted MRI scan showing a pituitary mass with expansion of the pituitary fossa (B) Coronal T1-weighted MRI scan showing a pituitary mass extending into the cavernous sinus, particularly on the right (C) Sagittal T1-weighted MRI scan of the pituitary tumor

  • T2-weighted axial MRI scan showing a lesion in the pituitary fossa (arrow), displaying heterogeneous

    T2-weighted axial MRI scan showing a lesion in the pituitary fossa (arrow), displaying heterogeneous signal intensity suggesting recent apoplexy

  • Lower uterine segment in patient with Asherman syndrome, seen on hysterosalpingogram

    Lower uterine segment in patient with Asherman syndrome, seen on hysterosalpingogram

Citations

    Key Articles

    • Practice Committee of the American Society for Reproductive Medicine. Current evaluation of amenorrhea: a committee opinion. Fertil Steril. 2024 Jul;122(1):52-61.[Abstract][Full Text]

    Referenced Articles

    • 1. Practice Committee of the American Society for Reproductive Medicine. Current evaluation of amenorrhea: a committee opinion. Fertil Steril. 2024 Jul;122(1):52-61.[Abstract][Full Text]

    • 2. Timmreck LS, Reindollar RH. Contemporary issues in primary amenorrhea. Obstet Gynecol Clin North Am. 2003 Jun;30(2):287-302.[Abstract]

    • 3. Pettersson F, Fries H, Nillius SJ. Epidemiology of secondary amenorrhea: incidence and prevalence rates. Am J Obstet Gynecol. 1973 Sep 1;117(1):80-6.[Abstract]

    • 4. Münster K, Helm P, Schmidt L. Secondary amenorrhoea: prevalence and medical contact--a cross-sectional study from a Danish county. Br J Obstet Gynaecol. 1992 May;99(5):430-3.[Abstract]

    • 5. Gimunová M, Paulínyová A, Bernaciková M, et al. The prevalence of menstrual cycle disorders in female athletes from different sports disciplines: a rapid review. Int J Environ Res Public Health. 2022 Oct 31;19(21):14243.[Abstract][Full Text]

    • 6. Stokić E, Srdić B, Barak O. Body mass index, body fat mass and the occurrence of amenorrhea in ballet dancers. Gynecol Endocrinol. 2005 Apr;20(4):195-9.[Abstract]

    • 7. Bacchi E, Spiazzi G, Zendrini G, et al. Low body weight and menstrual dysfunction are common findings in both elite and amateur ballet dancers. J Endocrinol Invest. 2013 May;36(5):343-6.[Abstract]

    • 8. Stuenkel CA, Gompel A, Davis SR, et al. Approach to the patient with new-onset secondary amenorrhea: is this primary ovarian insufficiency? J Clin Endocrinol Metab. 2022 Feb 17;107(3):825-35.[Abstract][Full Text]

    • 9. Mörö S, Kosola S, Holopainen E. Girls referred for amenorrhea: analysis of a patient series from a specialist center. Front Public Health. 2024;12:1304277.[Abstract][Full Text]

    • 10. Insler V. Gonadotropin therapy: new trends and insights. Int J Fertil. 1988 Mar-Apr;33(2):85-6;89-97.[Abstract]

    • 11. Munro MG, Balen AH, Cho S, et al. The FIGO ovulatory disorders classification system. Int J Gynaecol Obstet. 2022 Oct;159(1):1-20.[Abstract][Full Text]

    • 12. Gordon CM, Ackerman KE, Berga SL, et al. Functional hypothalamic amenorrhea: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2017 May 1;102(5):1413-39.[Abstract][Full Text]

    • 13. Bonazza F, Politi G, Leone D, et al. Psychological factors in functional hypothalamic amenorrhea: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023;14:981491.[Abstract][Full Text]

    • 14. Caronia LM, Martin C, Welt CK, et al. A genetic basis for functional hypothalamic amenorrhea. N Engl J Med. 2011 Jan 20;364(3):215-25.[Abstract][Full Text]

    • 15. Nash Z, Davies M. Premature ovarian insufficiency. BMJ. 2024 Mar 20;384:e077469.

    • 16. Verrilli L, Johnstone E, Welt C, et al. Primary ovarian insufficiency has strong familiality: results of a multigenerational genealogical study. Fertil Steril. 2023 Jan;119(1):128-34.[Abstract][Full Text]

    • 17. ​European Society of Human reproduction and Embryology. Guideline on premature ovarian insufficiency. 2024 [internet publication].[Full Text]

    • 18. Fenton AJ. Premature ovarian insufficiency: Pathogenesis and management. J Midlife Health. 2015 Oct-Dec;6(4):147-53.[Abstract][Full Text]

    • 19. Lee WL, Liu CH, Cheng M, et al. Focus on the primary prevention of intrauterine adhesions: current concept and vision. Int J Mol Sci. 2021 May 13;22(10):5175.[Abstract][Full Text]

    • 20. Böttcher B, Seeber B, Leyendecker G, et al. Impact of the opioid system on the reproductive axis. Fertil Steril. 2017 Aug;108(2):207-13.[Abstract][Full Text]

    • 21. Brenner SH, Lessing JB, Quagliarello J, et al. Hyperprolactinemia and associated pituitary prolactinomas. Obstet Gynecol. 1985;65:661-664.[Abstract]

    • 22. Management of acute obstructive uterovaginal anomalies: ACOG Committee opinion, number 779. Obstet Gynecol. 2019 Jun;133(6):e363-71.[Abstract][Full Text]

    • 23. Pitts S, DiVasta AD, Gordon CM. Evaluation and management of amenorrhea. JAMA. 2021 Nov 16;326(19):1962-3.

    • 24. Indirli R, Lanzi V, Mantovani G, et al. Bone health in functional hypothalamic amenorrhea: what the endocrinologist needs to know. Front Endocrinol (Lausanne). 2022;13:946695.[Abstract][Full Text]

    • 25. Ozgör B, Selimoğlu MA. Coeliac disease and reproductive disorders. Scand J Gastroenterol. 2010 Apr;45(4):395-402.[Abstract]

    • 26. Himel R, Keefe D. Evaluation and treatment of patients with hypothalamic hypogonadism. Obstet Gynecol Surv. 2025 Jul;80(7):427-31.[Abstract]

    • 27. Lim SS, Davies MJ, Norman RJ, et al. Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2012 Nov-Dec;18(6):618-37.[Abstract]

    • 28. Azziz R, Carmina E, Chen Z, et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016 Aug 11;2:16057.[Abstract]

    • 29. Sharma ST, Nieman LK, Feelders RA. Cushing's syndrome: epidemiology and developments in disease management. Clin Epidemiol. 2015;7:281-93.[Abstract]

    • 30. Husebye ES, Pearce SH, Krone NP, et al. Adrenal insufficiency. Lancet. 2021 Feb 13;397(10274):613-29.[Abstract]

    • 31. Brenner SH, Lessing JB, Quagliarello J, et al. Hyperprolactinemia and associated pituitary prolactinomas. Obstet Gynecol. 1985 May;65(5):661-4.[Abstract]

    • 32. Groff TR, Shulkin BL, Utiger RD, et al. Amenorrhea-galactorrhea, hyperprolactinemia, and suprasellar pituitary enlargement as presenting features of primary hypothyroidism. Obstet Gynecol. 1984 Mar;63(suppl 3):S86-9.[Abstract]

    • 33. Committee opinion no. 605: primary ovarian insufficiency in adolescents and young women. Obstet Gynecol. 2014 Jul;124(1):193-7.[Abstract][Full Text]

    • 34. Lopez LM, Grimes DA, Schulz KF, et al. Steroidal contraceptives: effect on bone fractures in women. Cochrane Database Syst Rev. 2014;(6):CD006033.[Abstract][Full Text]

    • 35. Kelesidis T, Kelesidis I, Chou S, et al. Narrative review: the role of leptin in human physiology: emerging clinical applications. Ann Intern Med. 2010;152:93-100.[Abstract][Full Text]

    • 36. Chou SH, Chamberland JP, Liu X, et al. Leptin is an effective treatment for hypothalamic amenorrhea. Proc Natl Acad Sci U S A. 2011 Apr 19;108(16):6585-90.[Abstract][Full Text]

    • 37. Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2010 Jul-Aug;16(4):347-63. [Abstract]

    • 38. Nelson LM. Clinical practice. Primary ovarian insufficiency. N Engl J Med. 2009 Feb 5;360(6):606-14.[Abstract][Full Text]

    • 39. Bakalov VK, Vanderhoof VH, Bondy CA, et al. Adrenal antibodies detect asymptomatic auto-immune adrenal insufficiency in young women with spontaneous premature ovarian failure. Hum Reprod. 2002 Aug;17(8):2096-100.[Abstract]

    • 40. Fleseriu M, Auchus R, Bancos I, et al. Consensus on diagnosis and management of Cushing's disease: a guideline update. Lancet Diabetes Endocrinol. 2021 Dec;9(12):847-75.[Abstract][Full Text]

    • 41. Gadelha M, Gatto F, Wildemberg LE, et al. Cushing's syndrome. Lancet. 2023 Dec 9;402(10418):2237-52.[Abstract]

Have feedback?
Tell us about your experience
Scroll to Top
epocrates logo

Sign in to access our clinical decision support tools

Sign inCreate Account
Download Epocrates from the App StoreDownload Epocrates from the Play Store
About UsFeaturesBusiness SolutionsHelp & Feedback
© 2026 epocrates, Inc.   Terms of UsePrivacy PolicyEditorial PolicyDo Not Sell or Share My Information